Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease.
Lorenzo BarbaMarkus OttoGiovanni BellomoFederico Paolini PaolettiSteffen HalbgebauerPatrick OecklPetra SteinackerFederico MassaLorenzo GaetaniLucilla ParnettiMarkus OttoPublished in: Journal of neurology, neurosurgery, and psychiatry (2022)
CSF β-syn increases in the whole AD continuum since the preclinical stage and represents a promising biomarker of synaptic damage in AD.